Cetuximab and Radiation Therapy in Treating Patients With Stage III-IV Head and Neck Cancer
Status:
Terminated
Trial end date:
2019-08-22
Target enrollment:
Participant gender:
Summary
This pilot clinical trial studies cetuximab and radiation therapy in treating patients with
stage III-IV head and neck cancer. Monoclonal antibodies, such as cetuximab, may block tumor
growth in different ways by targeting certain cells. Radiation therapy uses high energy x
rays to kill tumor cells. Drugs used in chemotherapy, such as cisplatin, work in different
ways to stop the growth of tumor cells, either by killing the cells, by stopping them from
dividing, or by stopping them from spreading. Giving cetuximab or cisplatin together with
radiation therapy may kill more tumor cells.
Phase:
N/A
Details
Lead Sponsor:
Rutgers, The State University of New Jersey
Collaborators:
National Cancer Institute (NCI) Rutgers Cancer Institute of New Jersey